Our study hypothesizes that this dual-targeted approach will provide superior disease control by addressing hyperuricemia and NLRP3-mediated inflammation, thereby reducing gout severity, preventing recurrent flares, and preserving joint integrity. This evidence concerns the gene NLRP3 and hyperuricemia.